Tomiyama Takahiro, Itoh Shinji, Iseda Norifumi, Toshida Katsuya, Kosai-Fujimoto Yukiko, Tomino Takahiro, Kurihara Takeshi, Nagao Yoshihiro, Morita Kazutoyo, Harada Noboru, Liu Yu-Chen, Ozaki Daisuke, Kohashi Kenichi, Oda Yoshinao, Mori Masaki, Yoshizumi Tomoharu
Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Single-Cell Genomics, Human Immunology, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Ann Surg Oncol. 2023 Jun;30(6):3378-3389. doi: 10.1245/s10434-022-13058-y. Epub 2023 Jan 15.
Signal regulatory protein alpha (SIRPα), expressed in the macrophage membrane, inhibits phagocytosis of tumor cells via CD47/SIRPα interaction, which acts as an immune checkpoint factor in cancers. This study aimed to clarify the clinical significance of SIRPα expression in hepatocellular carcinoma (HCC).
This study analyzed SIRPα expression using RNA sequencing data of 372 HCC tissues from The Cancer Genome Atlas (TCGA) and immunohistochemical staining of our 189 HCC patient cohort. The correlation between SIRPα expression and clinicopathologic factors, patient survival, and intratumor infiltration of immune cells was investigated.
Overall survival (OS) was significantly poorer with high SIRPα expression than with low expression in both TCGA and our cohort. High SIRPα expression correlated with lower recurrence-free survival (RFS) in our cohort. High SIRPα expression was associated with higher rates of microvascular invasion and lower serum albumin levels and correlated with greater intratumor infiltration of CD68-positive macrophages and myeloid-derived suppressor cells (MDSCs). Multivariate analysis showed that SIRPα expression and high infiltration of CD8-positive T cells and MDSCs were predictive factors for both RFS and OS. Patients with high SIRPα expression and infiltration of CD8-positive T cells and MDSCs had significantly lower RFS and OS rates. In spatial transcriptomics sequencing, SIRPα expression was significantly correlated with CD163 expression.
High SIRPα expression in HCC indicates poor prognosis, possibly by inhibiting macrophage phagocytosis of tumor cells, promoting MDSC infiltration and inducing antitumor immunity. Treatment alternatives using SIRPα blockage should be considered in HCC as inhibiting macrophage antitumor immunity and MDSCs.
信号调节蛋白α(SIRPα)在巨噬细胞膜上表达,通过CD47/SIRPα相互作用抑制肿瘤细胞的吞噬作用,该相互作用在癌症中作为一种免疫检查点因子。本研究旨在阐明SIRPα表达在肝细胞癌(HCC)中的临床意义。
本研究使用来自癌症基因组图谱(TCGA)的372例HCC组织的RNA测序数据以及我们的189例HCC患者队列的免疫组织化学染色分析SIRPα表达。研究了SIRPα表达与临床病理因素、患者生存以及肿瘤内免疫细胞浸润之间的相关性。
在TCGA队列和我们的队列中,SIRPα高表达组的总生存期(OS)显著低于低表达组。在我们的队列中,SIRPα高表达与较低的无复发生存期(RFS)相关。SIRPα高表达与较高的微血管侵犯率和较低的血清白蛋白水平相关,并且与CD68阳性巨噬细胞和髓源性抑制细胞(MDSC)在肿瘤内的浸润增加相关。多变量分析显示,SIRPα表达以及CD8阳性T细胞和MDSC的高浸润是RFS和OS的预测因素。SIRPα高表达且伴有CD8阳性T细胞和MDSC浸润的患者的RFS和OS率显著较低。在空间转录组学测序中,SIRPα表达与CD163表达显著相关。
HCC中SIRPα高表达提示预后不良,可能是通过抑制巨噬细胞对肿瘤细胞的吞噬作用、促进MDSC浸润以及诱导抗肿瘤免疫。由于抑制巨噬细胞抗肿瘤免疫和MDSC,HCC中应考虑使用SIRPα阻断的治疗方案。